Article
Real-world VISION trial demonstrates safety and efficacy of anti-VEGF in all AMD subtypes
One-year data from the pivotal Phase II/III VEGF Inhibition Study inOcular Neovascularization (VISION) indicate that selective anti-VEGF165(Macugen, Eyetech/Pfizer) treatment improves visual outcomes and offersa highly favorable systemic and ocular safety profile, said Steven Schwartz,MD.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
